Rhythm Pharmaceuticals(RYTM)
Focus: Rhythm Pharmaceuticals is a publicly traded specialty pharma company focused on peptide therapeutics for neurology, anchored by IMCIVREE (setmelanotide) for rare genetic obesity. The company is at peak commercialization phase with 201-500 employees and strong R&D investment.
Profile data last refreshed 11h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Employees
201-500
Open Jobs
58+25 this month
Hot — 32 jobs added in 30d
Net +25 (32 new, 7 removed). Aggressive expansion phase.
Should You Work at Rhythm Pharmaceuticals?
AI assessmentHigh-growth commercial play suitable for sales/marketing careers, but early-stage science fundamentals and cash-intensive model pose long-term sustainability risk.
Why Work Here
- Public company status provides liquidity, transparency, and institutional stability—rare for a 2024-founded entity focusing on peptide therapeutics.
- Commercial expansion is aggressive: 30 of 40 open roles are in Commercial, signaling rapid market launch infrastructure building for IMCIVREE.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$77M
Key Products
Peak8.0yr
FDA-approved MC4R agonist driving FY 2025 revenue growth; peak commercial phase with ~12-year patent runway.
Help build intelligence for Rhythm Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.